From J&J to BMS, New Jersey pharmaceutical companies continue to expand and transform through M&A, leadership shifts and ...

Merck aims to boost its business by buying Verona Pharma for $10 billion. Through the deal, it will add Ohtuvayre -- a ...

Private equity work is up year-over-year, but tariffs, inflation and valuations continue to be an issue for dealmakers.

Verona Pharma plc (NASDAQ:VRNA)’s shares experienced a boost in July when pharmaceutical giant Merck announced that it would ...

We came across a bullish thesis on Verona Pharma plc (VRNA) on Capital Employed’s Substack by Patients Capital Management. In ...

Merck & Co. ($MRK) is betting on acquisitions to offset the looming revenue loss from the upcoming patent expiration of ...

We recently published 14 Stocks Jim Cramer Discussed As He Talked About Record Bitcoin Price. Verona Pharma plc (NASDAQ:VRNA) ...

Pharmaceutical titan Merck & Co. Inc. has announced a landmark $10 billion acquisition of Verona Pharma plc, underscoring its ...

Merck’s recent acquisition announcement sends a strong signal regarding its urgency to tackle the impending Keytruda patent ...

This acquisition of Verona Pharma reflects the commitment we have to delivering innovative treatments to patients and our ...

A key patent for Merck’s blockbuster drug Keytruda will expire in 2028. The cancer therapy brought the company $29.5 billion last year. Keytruda may also face “ price setting ” from the Inflation ...

Verona Pharma, a year after receiving regulatory approval for its landmark chronic obstructive pulmonary disease (COPD) treatment, is being acquired by pharmaceutical giant Merck in a deal worth about ...